Reported clinical outcomes of injectable Leqembi in first year post-approval | Categorical | | | 7 months ago | |
Leqembi injectable available in the US within 3 months of FDA approval? | Binary | | | 7 months ago | |
Phase 4 studies for injectable Leqembi initiated within 6 months post-approval? | Binary | | | 7 months ago | |
Stock market response to FDA approval of injectable Leqembi | Categorical | | | 7 months ago | |
Market response to FDA approval of injectable Leqembi | Categorical | | | 7 months ago | |
Injectable Leqembi on U.S. market within 3 months post-approval? | Binary | | | 7 months ago | |
Global expansion of injectable Leqembi post-FDA approval | Categorical | | | 7 months ago | |
FDA approves injectable Leqembi by end of 2024? | Binary | | | 7 months ago | |
Global approval statuses of injectable Leqembi by end of 2025 | Categorical | | | 7 months ago | |
FDA approval of injectable Leqembi by end of 2024? | Binary | | | 7 months ago | |
Other pharma companies follow Eisai/Biogen by 2025? | Binary | | | 7 months ago | |
Clinical benefits of injectable Leqembi in the first year | Categorical | | | 7 months ago | |
When will Azitra's ATR-04 receive FDA approval? | Categorical | | | 3 months ago | |
Will Azitra's stock (AZTR) increase by 20% or more by December 31, 2024? | Binary | | | 3 months ago | |
When will Azitra's stock (AZTR) increase by 30% or more? | Categorical | | | 3 months ago | |
When will Azitra's ATR-04 enter Phase 3 clinical trials? | Categorical | | | 3 months ago | |
